Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P49720
UPID:
PSB3_HUMAN
Alternative names:
Proteasome chain 13; Proteasome component C10-II; Proteasome theta chain
Alternative UPACC:
P49720; P31147; Q0P6J7; Q96E27
Background:
The Proteasome subunit beta type-3, also known as Proteasome chain 13, Proteasome component C10-II, and Proteasome theta chain, is a pivotal non-catalytic component of the 20S core proteasome complex. This complex is crucial for the proteolytic degradation of most intracellular proteins, playing essential roles in maintaining cellular function by removing misfolded, damaged, or no longer needed proteins. It is involved in ATP-dependent and ubiquitin-independent protein degradation pathways, including spermatogenesis and the generation of MHC class I-presented antigenic peptides.
Therapeutic significance:
Understanding the role of Proteasome subunit beta type-3 could open doors to potential therapeutic strategies.